Compositions and methods for treating cancer
AssigneeAlpha Beta Holdings, LLC
InventorsDavid Cheresh, Sara Weis, Stephen McCormack, Christoph Rader, Hiromi Wettersten
Life of this patent
Estimating the term…
Abstract
The present invention relates to chimeric binding agents and compositions comprising the same. The invention further relates to polynucleotides encoding the chimeric binding agent and vectors and host cells comprising the same. The invention further relates to methods of using the chimeric binding agents to mediate antibody-dependent cellular cytotoxicity of epithelial cancer cells and methods of treating epithelial cell cancers.
Claims23
A chimeric binding agent comprising a first domain that specifically binds to integrin αvβ3 on an epithelial cancer cell expressing at least one mesenchymal cell marker and a second domain that mediates antibody-directed cellular cytotoxicity (ADCC) by engaging a macrophage that accumulates in mesenchymal tumors,
- wherein the first domain comprises the amino acid sequence of a light chain of hLM609-hIgG4-S228P (SEQ ID NO:2) and a Fab portion of a heavy chain of hLM609-hIgG4-S228P (SEQ ID NO:3);
- wherein the second domain comprises the amino acid sequence of a heavy chain Fc domain and hinge domain of hLM609-hIgG4-S228P (SEQ ID NO:4);
- and
- wherein the second domain comprises a S228P mutation, according to the EU numbering system, in the hinge domain.
Dependencies are inferred from the claim text.